SL
ALNY icon

Sentinus LLC’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sentinus LLC’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$218K Sell
658
-393
-37% -$134K 0.02% 534
2025
Q4 		$418K Buy
+1,051
New +$465K 0.04% 347

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sentinus LLC's ALNY Position: Q1 2026 in Review

Sentinus LLC reduced its Alnylam Pharmaceuticals (ALNY) stake by 37% in Q1 2026, selling an estimated $134K and leaving 658 shares worth $218K. The position accounts for 0.02% of the portfolio, ranked #534.

Sentinus LLC first reported a position in ALNY in Q4 2025 and has held it in 2 quarters since. The position peaked at $418K in Q4 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Sentinus LLC held 658 shares of Alnylam Pharmaceuticals worth $218K as of Q1 2026.
  • Sentinus LLC sold 393 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $134K.
  • Alnylam Pharmaceuticals made up 0.02% of Sentinus LLC's portfolio in Q1 2026, its #534 holding.
  • Sentinus LLC first reported a position in Alnylam Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Sentinus LLC's Alnylam Pharmaceuticals position peaked at $418K in Q4 2025.
  • 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Sentinus LLC's 13F filing for Q1 2026, filed 6 May 2026.